FDA OKs New CAR T-cell Lymphomas

The US Meals and Drug Administration (FDA) has permitted lisocabtagene maraleucel (Breyanzi), a chimeric antigen receptor (CAR) T-cell product for the therapy of adults with particular forms of relapsed or refractory huge B-cell lymphoma who relapse or fail to answer…